

Ali G Turhan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4722827/publications.pdf>

Version: 2024-02-01

52
papers

1,623
citations

471509

17
h-index

302126

39
g-index

59
all docs

59
docs citations

59
times ranked

2254
citing authors

#	ARTICLE	IF	CITATIONS
1	Evidence of Increased Hemangioblastic and Early Hematopoietic Potential in Chronic Myeloid Leukemia (CML)-derived Induced Pluripotent Stem Cells (iPSC). <i>StemJournal</i> , 2022, 4, 13-26.	0.6	3
2	Epigenetic and functional changes imposed by NUP98-HOXA9 in a genetically engineered model of chronic myeloid leukemia progression. <i>Haematologica</i> , 2021, 106, 881-885.	3.5	1
3	Molecular investigation of adequate sources of mesenchymal stem cells for cell therapy of COVID-19-associated organ failure. <i>Stem Cells Translational Medicine</i> , 2021, 10, 568-571.	3.3	25
4	Detection of Hematopoietic Stem Cell Transcriptome in Human Fetal Kidneys and Kidney Organoids Derived From Human Induced Pluripotent Stem Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 668833.	3.7	4
5	EGR1 dysregulation defines an inflammatory and leukemic program in cell trajectory of human-aged hematopoietic stem cells (HSC). <i>Stem Cell Research and Therapy</i> , 2021, 12, 419.	5.5	17
6	HLA-dependent heterogeneity and macrophage immunoproteasome activation during lung COVID-19 disease. <i>Journal of Translational Medicine</i> , 2021, 19, 290.	4.4	16
7	iPSC-Derived Organoids as Therapeutic Models in Regenerative Medicine and Oncology. <i>Frontiers in Medicine</i> , 2021, 8, 728543.	2.6	14
8	Co-occurrence of BCR-ABL1 rearrangement and CALR mutation in a single leukemic stem cell: evidence that BCR-ABL1 oncogenic addiction prevails over CALR signaling. <i>Leukemia and Lymphoma</i> , 2020, 61, 209-212.	1.3	3
9	PPAR β Cistrome Repression during Activation of Lung Monocyte-Macrophages in Severe COVID-19. <i>IScience</i> , 2020, 23, 101611.	4.1	31
10	Feeder-free and serum-free in vitro assay for measuring the effect of drugs on acute and chronic myeloid leukemia stem/progenitor cells. <i>Experimental Hematology</i> , 2020, 90, 52-64.e11.	0.4	6
11	Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia Patients. <i>Cancers</i> , 2020, 12, 3738.	3.7	10
12	Single-Cell Transcriptome in Chronic Myeloid Leukemia: Pseudotime Analysis Reveals Evidence of Embryonic and Transitional Stem Cell States. <i>Experimental Hematology</i> , 2020, 85, 47-56.e2.	0.4	0
13	Embryonic Program Activated during Blast Crisis of Chronic Myelogenous Leukemia (CML) Implicates a TCF7L2 and MYC Cooperative Chromatin Binding. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4057.	4.1	3
14	Evidence of <i>BCR-ABL1</i> -positive progenitor spread in blood during molecular recurrence after TKI discontinuation in chronic myeloid leukemia (CML). <i>Leukemia and Lymphoma</i> , 2020, 61, 1719-1723.	1.3	4
15	A novel neuronal organoid model mimicking glioblastoma (GBM) features from induced pluripotent stem cells (iPSC). <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2020, 1864, 129540.	2.4	14
16	iPSC-Derived Embryoid Bodies as Models of c-Met-Mutated Hereditary Papillary Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4867.	4.1	23
17	Modeling malignancies using induced pluripotent stem cells: from chronic myeloid leukemia to hereditary cancers. <i>Experimental Hematology</i> , 2019, 71, 61-67.	0.4	6
18	Global MicroRNA Profiling Uncovers miR-206 as a Negative Regulator of Hematopoietic Commitment in Human Pluripotent Stem Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1737.	4.1	1

#	ARTICLE	IF	CITATIONS
19	Generation of an induced pluripotent stem cell (iPSC) line from a patient with maturity-onset diabetes of the young type 3 (MODY3) carrying a hepatocyte nuclear factor 1-alpha (HNF1A) mutation. <i>Stem Cell Research</i> , 2018, 29, 56-59.	0.7	17
20	Superoxide dismutase 2 (SOD2) contributes to genetic stability of native and T315I-mutated BCR-ABL expressing leukemic cells. <i>Biochemical and Biophysical Research Communications</i> , 2018, 498, 715-722.	2.1	7
21	Transcriptional landscape of a RET C634Y -mutated iPSC and its CRISPR-corrected isogenic control reveals the putative role of EGR1 transcriptional program in the development of multiple endocrine neoplasia type 2A-associated cancers. <i>Stem Cell Research</i> , 2018, 26, 8-16.	0.7	15
22	Direct and rapid identification of T315I-Mutated BCR-ABL expressing leukemic cells using infrared microspectroscopy. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 1861-1867.	2.1	6
23	Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML). <i>Experimental Hematology</i> , 2018, 64, 71-83.e8.	0.4	5
24	Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML). <i>PLoS ONE</i> , 2018, 13, e0200923.	2.5	17
25	Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 473-474.	1.3	8
26	Whole-genome analysis reveals unexpected dynamics of mutant subclone development in a patient with JAK2-V617F-positive chronic myeloid leukemia. <i>Experimental Hematology</i> , 2017, 53, 48-58.	0.4	15
27	Generation of induced pluripotent stem cell (iPSC) line from a patient with triple negative breast cancer with hereditary exon 17 deletion of BRCA1 gene. <i>Stem Cell Research</i> , 2017, 24, 135-138.	0.7	22
28	Generation of an induced pluripotent stem cell (iPSC) line from a patient with maturity-onset diabetes of the young type 13 (MODY13) with a the potassium inwardly-rectifying channel, subfamily J, member 11 (KCNJ11) mutation. <i>Stem Cell Research</i> , 2017, 23, 178-181.	0.7	11
29	Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs). <i>Leukemia Research</i> , 2017, 60, 94-102.	0.8	19
30	Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex. <i>Oncotarget</i> , 2017, 8, 43662-43677.	1.8	18
31	Reversible skin telangiectasia induced by imatinib mesylate in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2731-2732.	1.3	1
32	Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation. <i>Oncotarget</i> , 2016, 7, 35293-35301.	1.8	54
33	The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia. <i>Experimental Hematology</i> , 2015, 43, 775-780.	0.4	21
34	A Bio-Integrative Approach Identifies an Inflammatory Signature in Chronic Myeloid Leukemia (CML) Stem Cells That Is Highly Perturbed in CML Blast Crisis and Involves REL transcription Factor. <i>Blood</i> , 2015, 126, 4017-4017.	1.4	0
35	Aryl Hydrocarbon Receptor (AhR) Pathway Directly Controls Hematopoietic Proliferation in Chronic Myeloid Leukemia (CML) and Its Inhibition Allows Massive Expansion of Leukemic Progenitors and Stem Cells. <i>Blood</i> , 2015, 126, 4013-4013.	1.4	0
36	Amniotic Fluid-Derived Mesenchymal Stem Cells Prevent Fibrosis and Preserve Renal Function in a Preclinical Porcine Model of Kidney Transplantation. <i>Stem Cells Translational Medicine</i> , 2014, 3, 809-820.	3.3	66

#	ARTICLE	IF	CITATIONS
37	Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease. <i>Journal of Clinical Oncology</i> , 2014, 32, 424-430.	1.6	355
38	Modeling the influence of stromal microenvironment in the selection of ENU-induced BCR-ABL1 mutants by tyrosine kinase inhibitors. <i>Oncoscience</i> , 2014, 1, 57-68.	2.2	18
39	Differential Contributions of STAT5A and STAT5B to Stress Protection and Tyrosine Kinase Inhibitor Resistance of Chronic Myeloid Leukemia Stem/Progenitor Cells. <i>Cancer Research</i> , 2013, 73, 2052-2058.	0.9	65
40	Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model. <i>Experimental Hematology</i> , 2013, 41, 335-345.e3.	0.4	8
41	Severe Acquired Bleeding Tendency Secondary To An Anti-Thrombin Antibody In a Patient With Monoclonal Gammopathy Of Unknown Significance: Direct In Vivo evidence. <i>Blood</i> , 2013, 122, 1111-1111.	1.4	0
42	O6-Methylguanine-Methyltransferase (MGMT) Promoter Methylation Status in Glioma Stem-Like Cells is Correlated to Temozolomide Sensitivity Under Differentiation-Promoting Conditions. <i>International Journal of Molecular Sciences</i> , 2012, 13, 6983-6994.	4.1	47
43	BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia. <i>Blood</i> , 2012, 119, 2964-2965.	1.4	22
44	Malignant Germ Cell-Like Tumors, Expressing Ki-1 Antigen (CD30), Are Revealed during in Vivo Differentiation of Partially Reprogrammed Human-Induced Pluripotent Stem Cells. <i>American Journal of Pathology</i> , 2012, 180, 2084-2096.	3.8	24
45	Identification of Spectral Modifications Occurring during Reprogramming of Somatic Cells. <i>PLoS ONE</i> , 2012, 7, e30743.	2.5	16
46	Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. <i>Blood</i> , 2011, 118, 3657-3660.	1.4	187
47	STAT5 as a CML target: STATinib therapies?. <i>Blood</i> , 2011, 117, 3252-3253.	1.4	8
48	Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. <i>Oncotarget</i> , 2011, 2, 713-727.	1.8	66
49	Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 2103-2111.	1.3	14
50	Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells. <i>Oncogene</i> , 2003, 22, 4102-4110.	5.9	54
51	Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. <i>Blood</i> , 2003, 101, 4583-4588.	1.4	94
52	BCR-ABL down-regulates the DNA repair protein DNA-PKcs. <i>Blood</i> , 2001, 97, 2084-2090.	1.4	155